PAREA in Cork: mental health across policies and the role of psychological care

Mental health is shaped by decisions across government, from employment and education to housing and public spending. How to give it greater consideration in policymaking was a central theme at “Resilient Europe: Mental Health as a Strategic Asset for Europe’s Strength and Competitiveness,” held at University College Cork on 15 October 2026.

Representing PAREA, Tadeusz Hawrot joined policymakers and experts at the Irish EU Presidency event to discuss mental health policy and resilience. A recurring message was that mental health should be considered from the outset when policies are developed, across all sectors.

The conference was opened by Mary Butler, Ireland’s Minister for Mental Health and Government Chief Whip. Her combined responsibilities provided a reference point for discussions about how mental health can have a stronger voice in government decision-making.

Psychological therapies and patient preferences

Tadeusz particularly valued the contribution of Prof. David Clark, whose work has helped shape the development and delivery of evidence-based psychological treatments.

Clark discussed progress in psychological therapies and their place as recommended first-line interventions for many mental health conditions. He also highlighted patient preferences, citing a ratio of three to one in favour of psychological therapy over medication.

This raised a question relevant to psychedelic treatments: how do they fit into that distinction?

Psychedelics are often understood primarily as another drug treatment. Yet when delivered within a model that includes preparation, psychological support and integration, their therapeutic use involves both pharmacological and psychological elements. Tadeusz described this approach as “drug-supported psychological therapies.”

This perspective has practical implications for how treatments are researched, funded and delivered. It directs attention to the care surrounding administration, as well as to the medicine itself.

Understanding what care contributes

As developers seek to make psychedelic treatments shorter, simpler and more scalable, the role of psychological support requires careful investigation.

There are understandable pressures to reduce costs and make treatment easier to deliver. At the same time, removing support without understanding its contribution could overlook an important part of care.

The research task is to establish which elements of psychological support contribute to outcomes, for whom and at what intensity. Different patients may need different forms and levels of support, and delivery models should be informed by evidence about those needs.

For PAREA, these questions connect directly to responsible access. Regulatory pathways, reimbursement decisions and service planning will help determine the care patients can receive. Psychological support, professional training and continuity of care need to be considered as those systems develop.

The discussions in Cork offered an opportunity to consider psychedelic therapies within the wider mental health agenda: how Europe can support effective treatments, respond to patient preferences and make mental health a consideration across public policy.

Previous
Previous

PAREA at THE REAL Summit NYC: access, adoption and the future of psychedelic care

Next
Next

Guest perspective from Julien Chupin and Amandine Luquiens, CHU de Nîmes